Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)

Tianyuan Pan; Chuyan Li

doi:doi:10.11648/j.cmr.20251406.14

Review Article |

| Peer-Reviewed

Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)

Tianyuan Pan^*

, Chuyan Li

Published in Clinical Medicine Research (Volume 14, Issue 6)

Received: 15 October 2025 Accepted: 27 October 2025 Published: 29 December 2025

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective This study seeks to explore the association between common clinical indicators and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Methods A cohort of 52 women with PCOS, 22 with isolated polycystic ovarian morphology (PCOM), 13 with isolated hyperandrogenism (HA), and 59 healthy controls was recruited from the Department of Reproductive Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, between June 2021 and September 2022. Clinical parameters including age and body mass index (BMI) were recorded, while levels of D-dimer (DD), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (Cr), urea nitrogen (UN), fasting plasma glucose (Glu), fasting insulin (Fins), and thyroid-stimulating hormone (TSH), embryo availability rate, fertilization Rate were measured. Differences across PCOS, PCOM, and HA groups were analyzed using analysis of variance and non-parametric tests. Results (1) In the PCOS group, significant differences were observed for embryo availability rate, age, WBC, TSH, ALT, AST, MAFLD, and BARD scores (P < 0.05). (2) Embryo availability was inversely associated with age, MAFLD, BARD, Fins, TSH, and WBC, and positively associated with AST (P < 0.05). (3) Fertilization rate was negatively correlated with V-PH, CA125, granulocyte percentage, BMI, Cr, and UN/Cr (P < 0.05). (4) ROC analysis of pregnancy outcomes in PCOS patients demonstrated that age, ALT, AST, AST/ALT, Cr, UN/Cr, DD, TSH, and CA125 had areas, sensitivities, and specificities above the moving average threshold. Conclusion Endocrine profiles differ significantly among PCOS, PCOM, and HA groups, and markers such as Age, ALT, AST, AST/ALT ratio, Cr, UN/Cr, DD, TSH, and CA125 can serve as potential predictors of pregnancy outcomes in patients with PCOS.

Published in	Clinical Medicine Research (Volume 14, Issue 6)
DOI	10.11648/j.cmr.20251406.14
Page(s)	229-237
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2025. Published by Science Publishing Group

Keywords

Polycystic Ovary Syndrome, Pregnancy Outcomes, Clinical Indicators, Inflammation, Endocrine

References

[1]	Ioannis G, Lempesis, Samuel J, Apple, Gustavo, Duarte et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. [J]. Diabetes Metab Res Rev, 2023, 39: e3634. https://doi.org/10.1002/dmrr.3634
[2]	Anastasia, Trouva, Michael, Alvarsson, Jan, Calissendorff et al. Maternal thyroid function and offspring birth anthropometrics in women with polycystic ovary syndrome. [J]. Front Endocrinol (Lausanne), 2024, 15: 1343277. https://doi.org/10.3389/fendo.2024.1343277
[3]	Cesta CE, Öberg AS, Ibrahimson A, et al. Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: Prenatal androgen exposure or genetic confounding?. Psychol Med. 2020; 50(4): 616-624. https://doi.org/10.1017/S0033291719000424
[4]	Wu Q, Gao J, Bai D, Yang Z, Liao Q. The prevalence of polycystic ovarian syndrome in Chinese women: A meta-analysis. Ann Palliat Med. 2021; 10(1): 74-87. https://doi.org/10.21037/apm-20-1881
[5]	David H, Abbott, Daniel A, Dumesic. Monoclonal antibody therapy for PCOS? [J]. Cell Metab, 2025, 37(2): 211-213. https://doi.org/10.1016/j.cmet.2024.12.009 (Note: 2025 article, verify upon publication).
[6]	Cotellessa L, Sobrino V, Silva MSB, et al. Preventing and correcting polycystic ovary syndrome by targeting anti-Müllerian hormone signaling in minipuberty and adulthood in mice. [J]. Cell Metab, 2025, 37(2): 248-262. e6. https://doi.org/10.1016/j.cmet.2024.11.013
[7]	Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome. [J]. Endocr Rev, 2020, 41(4): bnaa010. https://doi.org/10.1210/endrev/bnaa010
[8]	Fischer MB, Mola G, Rom AL, et al. Ovarian and Uterine Morphology in Minipuberty: Associations With Reproductive Hormones: a COPANA Study of 302 Girls. J Clin Endocrinol Metab. 2025; 110(4): 1015-1022. https://doi.org/10.1210/clinem/dgad738
[9]	Abbott DH, Levine JE, Dumesic PA, et al. POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome. [J]. Reproduction, 2025, 170(1): R1-R12. https://doi.org/10.1530/REP-23-0548
[10]	Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022; 10(9): 668-680. https://doi.org/10.1016/S2213-8587(22)00163-2
[11]	di Clemente N, Racine C, Pierre A, et al. Anti-Müllerian Hormone in Female Reproduction. [J]. Endocr Rev, 2021, 42(6): 753-782. https://doi.org/10.1210/endrev/bnab012
[12]	Dapas M, Dunaif A. Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. [J]. Endocr Rev, 2022, 43(6): 927-965. https://doi.org/10.1210/endrev/bnac001
[13]	Kazemi M, Kim JY, Wan C, et al. Comparison of dietary and physical activity behaviors in women with and without polycystic ovary syndrome: a systematic review and meta-analysis of 39 471 women. [J]. Hum Reprod Update, 2022, 28(6): 910-955. https://doi.org/10.1093/humupd/dmac023
[14]	Geng L, Yang X, Sun J, et al. Gut Microbiota Modulation by Inulin Improves Metabolism and Ovarian Function in Polycystic Ovary Syndrome. [J]. Adv Sci (Weinh), 2025, 12(8): e2308401. https://doi.org/10.1002/advs.202308401
[15]	Martínez-García MÁ, Luque-Ramírez M, San-Millán JL, et al. Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. [J]. Diabetes Care, 2009, 32(5): 934-936. https://doi.org/10.2337/dc08-1962
[16]	Chen YH, Heneidi S, Lee JM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013; 62(7): 2278-2286. https://doi.org/10.2337/db12-0963
[17]	Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during menopause: a meta-analysis. Am J Obstet Gynecol. 2019; 221(5): 393-409. https://doi.org/10.1016/j.ajog.2019.04.023
[18]	Xiao Peng, Ren Jingjing, Yao Lingnu, et al. Longitudinal study of chronic low-grade inflammatory response in polycystic ovary syndrome: preliminary compilation and analysis of inflammation and related endocrine risk indicators [J]. General Practice Clinical and Education, 2021, 19(02): 102-107.
[19]	Torstensson S, Ascani A, Risal S, et al. Androgens Modulate the Immune Profile in a Mouse Model of Polycystic Ovary Syndrome. [J]. Adv Sci (Weinh), 2024, 11(5): e2304470. https://doi.org/10.1002/advs.202304470
[20]	Lang Q, Yang Y, Zhang X, et al. Etanercept-mediated anti-TNF-α therapy ameliorates the phenotype of PCOS model induced by letrozole. PLoS One. 2019; 14(6): e0217495. https://doi.org/10.1371/journal.pone.0217495
[21]	Papadakis G, Hans D, Gonzalez Rodriguez E, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity: The osteolaus cohort. J Clin Endocrinol Metab. 2018; 103(5): 1948-1957. https://doi.org/10.1210/jc.2017-02458
[22]	Qi X, Zhang B, Zhao Y, et al. Hyperhomocysteinemia Promotes Insulin Resistance and Adipose Tissue Inflammation in PCOS Mice Through Modulating M2 Macrophage Polarization via Estrogen Suppression. [J]. Endocrinology, 2017, 158(10): 3591-3603. https://doi.org/10.1210/en.2017-00629

Cite This Article

Plain Text BibTeX RIS

APA Style

Pan, T., Li, C. (2025). Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clinical Medicine Research, 14(6), 229-237. https://doi.org/10.11648/j.cmr.20251406.14

Copy | Download

ACS Style

Pan, T.; Li, C. Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clin. Med. Res. 2025, 14(6), 229-237. doi: 10.11648/j.cmr.20251406.14

Copy | Download

AMA Style

Pan T, Li C. Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clin Med Res. 2025;14(6):229-237. doi: 10.11648/j.cmr.20251406.14

Copy | Download

@article{10.11648/j.cmr.20251406.14,
  author = {Tianyuan Pan and Chuyan Li},
  title = {Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)},
  journal = {Clinical Medicine Research},
  volume = {14},
  number = {6},
  pages = {229-237},
  doi = {10.11648/j.cmr.20251406.14},
  url = {https://doi.org/10.11648/j.cmr.20251406.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20251406.14},
  abstract = {Objective This study seeks to explore the association between common clinical indicators and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Methods A cohort of 52 women with PCOS, 22 with isolated polycystic ovarian morphology (PCOM), 13 with isolated hyperandrogenism (HA), and 59 healthy controls was recruited from the Department of Reproductive Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, between June 2021 and September 2022. Clinical parameters including age and body mass index (BMI) were recorded, while levels of D-dimer (DD), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (Cr), urea nitrogen (UN), fasting plasma glucose (Glu), fasting insulin (Fins), and thyroid-stimulating hormone (TSH), embryo availability rate, fertilization Rate were measured. Differences across PCOS, PCOM, and HA groups were analyzed using analysis of variance and non-parametric tests. Results (1) In the PCOS group, significant differences were observed for embryo availability rate, age, WBC, TSH, ALT, AST, MAFLD, and BARD scores (P Conclusion Endocrine profiles differ significantly among PCOS, PCOM, and HA groups, and markers such as Age, ALT, AST, AST/ALT ratio, Cr, UN/Cr, DD, TSH, and CA125 can serve as potential predictors of pregnancy outcomes in patients with PCOS.},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)
AU  - Tianyuan Pan
AU  - Chuyan Li
Y1  - 2025/12/29
PY  - 2025
N1  - https://doi.org/10.11648/j.cmr.20251406.14
DO  - 10.11648/j.cmr.20251406.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 229
EP  - 237
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20251406.14
AB  - Objective This study seeks to explore the association between common clinical indicators and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Methods A cohort of 52 women with PCOS, 22 with isolated polycystic ovarian morphology (PCOM), 13 with isolated hyperandrogenism (HA), and 59 healthy controls was recruited from the Department of Reproductive Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, between June 2021 and September 2022. Clinical parameters including age and body mass index (BMI) were recorded, while levels of D-dimer (DD), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (Cr), urea nitrogen (UN), fasting plasma glucose (Glu), fasting insulin (Fins), and thyroid-stimulating hormone (TSH), embryo availability rate, fertilization Rate were measured. Differences across PCOS, PCOM, and HA groups were analyzed using analysis of variance and non-parametric tests. Results (1) In the PCOS group, significant differences were observed for embryo availability rate, age, WBC, TSH, ALT, AST, MAFLD, and BARD scores (P Conclusion Endocrine profiles differ significantly among PCOS, PCOM, and HA groups, and markers such as Age, ALT, AST, AST/ALT ratio, Cr, UN/Cr, DD, TSH, and CA125 can serve as potential predictors of pregnancy outcomes in patients with PCOS.
VL  - 14
IS  - 6
ER  -

Copy | Download

Author Information

Tianyuan Pan

Department of General Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Contact Email

http://orcid.org/0000-0002-8947-5058
Chuyan Li

Department of Reproductive Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Contact Email

http://orcid.org/0000-0003-3094-5710

Download PDF

Submit an Article

Sections

Plain Text BibTeX RIS

APA Style

Pan, T., Li, C. (2025). Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clinical Medicine Research, 14(6), 229-237. https://doi.org/10.11648/j.cmr.20251406.14

Copy | Download

ACS Style

Pan, T.; Li, C. Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clin. Med. Res. 2025, 14(6), 229-237. doi: 10.11648/j.cmr.20251406.14

Copy | Download

AMA Style

Pan T, Li C. Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS). Clin Med Res. 2025;14(6):229-237. doi: 10.11648/j.cmr.20251406.14

Copy | Download

@article{10.11648/j.cmr.20251406.14,
  author = {Tianyuan Pan and Chuyan Li},
  title = {Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)},
  journal = {Clinical Medicine Research},
  volume = {14},
  number = {6},
  pages = {229-237},
  doi = {10.11648/j.cmr.20251406.14},
  url = {https://doi.org/10.11648/j.cmr.20251406.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20251406.14},
  abstract = {Objective This study seeks to explore the association between common clinical indicators and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Methods A cohort of 52 women with PCOS, 22 with isolated polycystic ovarian morphology (PCOM), 13 with isolated hyperandrogenism (HA), and 59 healthy controls was recruited from the Department of Reproductive Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, between June 2021 and September 2022. Clinical parameters including age and body mass index (BMI) were recorded, while levels of D-dimer (DD), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (Cr), urea nitrogen (UN), fasting plasma glucose (Glu), fasting insulin (Fins), and thyroid-stimulating hormone (TSH), embryo availability rate, fertilization Rate were measured. Differences across PCOS, PCOM, and HA groups were analyzed using analysis of variance and non-parametric tests. Results (1) In the PCOS group, significant differences were observed for embryo availability rate, age, WBC, TSH, ALT, AST, MAFLD, and BARD scores (P Conclusion Endocrine profiles differ significantly among PCOS, PCOM, and HA groups, and markers such as Age, ALT, AST, AST/ALT ratio, Cr, UN/Cr, DD, TSH, and CA125 can serve as potential predictors of pregnancy outcomes in patients with PCOS.},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Association of Common Clinical Indicators with Pregnancy Outcomes in Polycystic Ovary Syndrome (PCOS)
AU  - Tianyuan Pan
AU  - Chuyan Li
Y1  - 2025/12/29
PY  - 2025
N1  - https://doi.org/10.11648/j.cmr.20251406.14
DO  - 10.11648/j.cmr.20251406.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 229
EP  - 237
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20251406.14
AB  - Objective This study seeks to explore the association between common clinical indicators and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Methods A cohort of 52 women with PCOS, 22 with isolated polycystic ovarian morphology (PCOM), 13 with isolated hyperandrogenism (HA), and 59 healthy controls was recruited from the Department of Reproductive Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, between June 2021 and September 2022. Clinical parameters including age and body mass index (BMI) were recorded, while levels of D-dimer (DD), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (Cr), urea nitrogen (UN), fasting plasma glucose (Glu), fasting insulin (Fins), and thyroid-stimulating hormone (TSH), embryo availability rate, fertilization Rate were measured. Differences across PCOS, PCOM, and HA groups were analyzed using analysis of variance and non-parametric tests. Results (1) In the PCOS group, significant differences were observed for embryo availability rate, age, WBC, TSH, ALT, AST, MAFLD, and BARD scores (P Conclusion Endocrine profiles differ significantly among PCOS, PCOM, and HA groups, and markers such as Age, ALT, AST, AST/ALT ratio, Cr, UN/Cr, DD, TSH, and CA125 can serve as potential predictors of pregnancy outcomes in patients with PCOS.
VL  - 14
IS  - 6
ER  -

Copy | Download